References
- National Kidney Foundation. National kidney foundation kidney disease outcomes quality initiative. Available at: http://www.kidney.org/professionals/doqi/ kdoqi/p5_lab_g4.htm. Accessed December 09, 2011
- Alessandra CB, Marion SA, Natália CM, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. CJASN. 2008;3(2):348–354
- Fried LF, Boudreau R, Lee JS, et al. Health, aging and body composition study. Kidney function as a predictor of loss of lean mass in older adults: health, aging and body composition study. J Am Geriatr Soc. 2007;55(10):1578–1584
- CA Jones, GM McQuillan, JW Kusek, et al. Serum Creatinine Levels in the US Population: Third National Health and Nutrition Examination Survey; Epidemiology, Clinical Trials, and End-Stage Renal Disease and Minority Health Programs. Bethesda, MD: DKUHD, NIDDK, NIH; 1998
- Howlett HCS, Bailey CJ. A risk–benefit assessment of Metformin in type 2 diabetes mellitus. Drug Saf. 1999;20:489–503
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
- Calabrese AT, Coley KC, DaPos SV, et al. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002;162:434–437
- Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998;338:265–266
- Morley JE. Diabetes mellitus: new approaches to management. Clin Geriatrics. 1996;4:75–81
- Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of Metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther. 1978;24(6):683–693
- Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. Ottawa: The Association; 2001
- Edelman SV. Prescribing oral antidiabetic agents: general considerations. Clin Diabetes. 1998;16:37–41
- Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med. 2007;24:1160–1163
- Lardinois CK. Type 2 diabetes: glycemic targets and oral therapies for older patients. Geriatrics. 1998;53(11):22–34
- Bell DSH. Prudent utilization of the presently available treatment modalities for type 2 diabetes. Endocrinologist. 1998;8:332–331
- Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev. 1998;6:89–131
- Herrington WG, Levy JB. Metformin: effective and safe in renal disease? Int Urol Nephrol. 2008;40:411–417
- Robinson JD, Lupkiewicz SM, Palenik L, et al. Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm. 1983;40(6):1016–1019
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41